JP5486602B2 - ベンゾオキサゾール化合物および使用方法 - Google Patents

ベンゾオキサゾール化合物および使用方法 Download PDF

Info

Publication number
JP5486602B2
JP5486602B2 JP2011529267A JP2011529267A JP5486602B2 JP 5486602 B2 JP5486602 B2 JP 5486602B2 JP 2011529267 A JP2011529267 A JP 2011529267A JP 2011529267 A JP2011529267 A JP 2011529267A JP 5486602 B2 JP5486602 B2 JP 5486602B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
pharmaceutically acceptable
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011529267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504133A (ja
JP2012504133A5 (enExample
Inventor
チェン，ワンジュン
スパイヴィー，マーク
グソフスキー，ファビアン
イシザカ，サリー・ティー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2012504133A publication Critical patent/JP2012504133A/ja
Publication of JP2012504133A5 publication Critical patent/JP2012504133A5/ja
Application granted granted Critical
Publication of JP5486602B2 publication Critical patent/JP5486602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2011529267A 2008-09-26 2009-09-25 ベンゾオキサゾール化合物および使用方法 Active JP5486602B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10067808P 2008-09-26 2008-09-26
US61/100,678 2008-09-26
PCT/US2009/058398 WO2010036905A1 (en) 2008-09-26 2009-09-25 Benzoxazole compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2012504133A JP2012504133A (ja) 2012-02-16
JP2012504133A5 JP2012504133A5 (enExample) 2012-11-01
JP5486602B2 true JP5486602B2 (ja) 2014-05-07

Family

ID=41203923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011529267A Active JP5486602B2 (ja) 2008-09-26 2009-09-25 ベンゾオキサゾール化合物および使用方法

Country Status (4)

Country Link
US (1) US8354400B2 (enExample)
EP (1) EP2350032B1 (enExample)
JP (1) JP5486602B2 (enExample)
WO (1) WO2010036905A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072891A1 (en) 2015-03-24 2016-09-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New Toll-Like Receptor 9 Antagonists
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109715617B (zh) 2016-07-30 2022-04-19 百时美施贵宝公司 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
ES2902504T3 (es) 2016-09-09 2022-03-28 Bristol Myers Squibb Co Compuestos de indol sustituidos con piridilo
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
EP3661926B1 (en) 2017-08-04 2022-02-23 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
CN107759532B (zh) * 2017-11-23 2021-02-12 苏州大学 一种苯并噁唑-2-乙基肟衍生物、其制备方法及应用
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
WO2019126081A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EA202091474A1 (ru) * 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効なアミノインドール化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
TW202440078A (zh) 2021-09-10 2024-10-16 美商基利科學股份有限公司 噻吩并吡咯化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AR045955A1 (es) 2003-09-30 2005-11-16 Janssen Pharmaceutica Nv Compuestos benzoimidazolicos
TW200612925A (en) * 2004-08-26 2006-05-01 Wyeth Corp Prodrug substituted benzoxazoles as estrogenic agents
AU2006320556A1 (en) 2005-12-01 2007-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins

Also Published As

Publication number Publication date
JP2012504133A (ja) 2012-02-16
EP2350032B1 (en) 2016-05-25
WO2010036905A1 (en) 2010-04-01
US8354400B2 (en) 2013-01-15
EP2350032A1 (en) 2011-08-03
US20110183967A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
EP2350032B1 (en) Benzoxazole compounds and methods of use
JP6856900B2 (ja) トール様受容体７またはトール様受容体９の活性化阻害剤
JP5908455B2 (ja) Ｃｇｒｐ受容体アンタゴニスト
KR101783632B1 (ko) 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
JP2011514364A (ja) 置換されたピロリジン及びピペリジン化合物、その誘導体、並びに疼痛を治療するための方法
JP2019508475A (ja) 化合物（ｓ）−４−（（ｓ）−３−フルオロ−３−（２−（５，６，７，８−テトラヒドロ−１，８−ナフチリジン−２−イル）エチル）ピロリジン−１−イル）−３−（３−（２−メトキシエトキシ）フェニル）ブタン酸のクエン酸塩
CN115433212B (zh) 作为免疫调节剂的联苯类化合物及其制备方法和应用
US12016836B2 (en) Compositions and methods for reducing immune intolerance and treating autoimmune disorders
US20250114361A1 (en) Pyrazolopyrimidine compound and pharmaceutical use thereof
RU2727194C2 (ru) Гетероциклические соединения для лечения заболевания
US20240207265A1 (en) TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
JP2022545047A (ja) ３－ヒドロキシ－５－プレグナン－２０－オン誘導体およびその使用
US8802734B2 (en) Method of treating or preventing pain
JP3939369B2 (ja) β３ −アドレナリン作動薬として作用する｛（７Ｓ）−７−［（２Ｒ）−２−（３−クロロフェニル）−２−ヒドロキシエチルアミノ］−５，６，７，８−テトラヒドロナフタレン−２−イルオキシ）酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
CA2679301C (en) Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases
JP2007523871A (ja) ケモカイン受容体活性の７および８員複素環式シクロペンチルベンジルアミドモジュレーター
US20250214951A1 (en) 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient
JP2025536344A (ja) ｓＧＣ刺激剤でのミトコンドリア疾患の処置
US20130137693A1 (en) Lisofylline analogs and methods for use
JP2025527188A (ja) Ｎｌｒｐ３阻害剤の投与計画
US20230137021A1 (en) Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents
WO2007133803A2 (en) Treatment of mycobacterial infections
TW202219047A (zh) 靶向gpr35之治療劑
TWI644913B (zh) Bace1抑制劑
US20100105690A1 (en) Lisofylline analogs and methods for use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140221

R150 Certificate of patent or registration of utility model

Ref document number: 5486602

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250